News & Events

A new method developed by UNSW Sydney medical researchers offers a way to predict whether patients with the blood condition myelodysplastic syndrome will respond to treatment. Myelodysplastic syndrome (MDS) is characterised by impaired peripheral blood cell production and abnormal bone marrow, and more than 1400 people in Australia are diagnosed with the disease each year. MDS is much more common in older individuals and, if left untreated, the prognosis can be very poor.

A group of researchers led by UNSW Sydney has developed a new gene therapy that may reverse the devastating symptoms of brain disorders such as Canavan disease. Canavan disease is a rare, fatal genetic disorder in which an enzyme called aspartoacylase is not active. This enzyme breaks down the amino acid NAA in the body.

UNSW Sydney will play a role in a new national consortium that gives students formal internships in clinical research, funded by MTPConnect. MTPConnect – the Medical Technologies and Pharmaceuticals Industry Growth Centre – today announced it would provide a proposed $250,000 provisional funding to the program called "ACCELERATE: building the talent pool" over two years, with proposed matched funding of $250,000 from the sector.

Call for abstracts – UNSW Medicine Learning & Teaching forum Medicine’s 2017 Learning & Teaching forum will be held on Friday 1 December from 9am to 2 pm in WW G02 Wallace Wurth Bldg (Kensington).Proposals for presentations (maximum 200-word abstract) should be emailed for review to Gary Velan g.velan@unsw.edu.au by 5pm, 15 November 2017. Note: presentations on the day are 10 mins + 5 mins Q&A.